A Medicine study used artificial intelligence to discover a naturally occurring molecule, specifically, a peptide, that ...

Proteins in the sheath of cellular protrusions control how effectively cells can adhere to surfaces. Biological cells often ...

Patients with diabetes taking a semaglutide medication face a higher risk of NAION, a potentially debilitating ophthalmic condition. Semaglutide medication use is linked with a greater risk of ...

Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Patients with diabetes who take semaglutide are at increased risk for NAION compared with patients who do not use GLP-1 RAs to control their blood sugar, a new study finds.

The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic optic ...

The rise of these medications is causing many patients to experience what's now commonly known as 'Ozempic face,' a term coined by New York-based dermatologist Paul Jarrod Frank, MD that refers to the ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...